Formycon Begins Biosimilar Ustekinumab Trial
Phase I Trial Announcement Comes Shortly After NeuClone
Formycon has become the latest firm to announce a Phase I trial for a proposed biosimilar ustekinumab rival to Janssen’s Stelara, following hot on the heels of NeuClone.
You may also be interested in...
China’s Bio-Thera solutions has announced the start of Phase I trials for its ustekinumab biosimilar. The project is one among several potential rivals to Stelara in the works from a host of developers.
Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.
Australia’s NeuClone has reported the completion of subject visits in its Phase I trial for a biosimilar ustekinumab rival to Janssen’s Stelara, with favorable results seen ahead of the formal study report that is due in the third quarter of this year.